ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Proapoptotic function of integrin beta(3) in human hepatocellular carcinoma cells.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of gene expression profiles indicates genes in spliceosome pathway are up-regulated in hepatocellular carcinoma (HCC).Medical oncology (Northwood, London, England) · 2015Pooled it
- Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model.Journal of translational internal medicine · 2026Article
- ECM remodeling in hypothyroidism-associated MAFLD: mechanisms, clinical relevance, and therapeutic targets.Frontiers in immunology · 2025Review
- Review
- Integrins and NAFLD-associated liver diseases: clinical associations, pathophysiological mechanisms and pharmacological implications.Acta biochimica et biophysica Sinica · 2024Review
- Genome-Wide Methylation Mapping Using Nanopore Sequencing Technology Identifies Novel Tumor Suppressor Genes in Hepatocellular Carcinoma.International journal of molecular sciences · 2021Article
- Administration of GDF3 Into Septic Mice Improves SurvivalFrontiers in immunology · 2021Article
- Mechano-signalling, induced by fullerene CInternational journal of nanomedicine · 2019Article
- A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer.BMC genomics · 2017Article
- Multidimensional Roles of Collagen Triple Helix Repeat Containing 1 (CTHRC1) in Malignant Cancers.Journal of Cancer · 2016Review
- Controlling the Balance of Fibroblast Proliferation and Differentiation: Impact of Thy-1.The Journal of investigative dermatology · 2015Article
- Collagen triple helix repeat containing 1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation and motility.International journal of oncology · 2014Article
- Hepatitis C virus infection: establishment of chronicity and liver disease progression.EXCLI journal · 2014Review
- Fibrosis-dependent mechanisms of hepatocarcinogenesis.Hepatology (Baltimore, Md.) · 2012Review
- Acquisition of anoikis resistance through CD147 upregulation: A new mechanism underlying metastasis of hepatocellular carcinoma cells.Oncology letters · 2012Article
- Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression.PloS one · 2012Article
- The conditioned medium from a stable human GDF3-expressing CHO cell line, induces the differentiation of PC12 cells.Molecular and cellular biochemistry · 2012Article
- Dual effects of β3 integrin subunit expression on human pancreatic cancer models.Cellular oncology (Dordrecht, Netherlands) · 2011Article
- The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets.Seminars in cancer biology · 2011Review
- N-terminal and C-terminal heparin-binding domain polypeptides derived from fibronectin reduce adhesion and invasion of liver cancer cells.BMC cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThis study evaluates the proapoptotic function of integrin beta(3) in human hepatocellular carcinoma (HCC). EXPERIMENTAL
designThe expression of integrin beta(3) in 67 HCC specimens paired with corresponding neighboring nontumorous tissue was studied by quantitative real-time PCR and Western blot. The proapoptotic function of integrin beta(3) in SMMC-7721 human hepatoma cells overexpressing ITGB3 (gene coding integrin beta(3)) was determined through colony formation, serum starvation, and anoikis assay.
resultsCompared with neighboring pathologically normal liver tissue, approximately 60% of the HCC specimens showed a significant down-regulated level of integrin beta(3) expression. Transient expression of integrin beta(3) in SMMC-7721 resulted in an enhanced level of apoptosis and suppression of colony formation. Cell growth inhibition on serum/ligand deprivation and incidences of anoikis were remarkably increased in SMMC-7721 with stable expression of integrin beta(3) in comparison with vector control transfectants. In addition, expression of fibrinogen and vitronectin, two native ligands for integrin alpha(v)beta(3) in liver, was inhibited, which was correlated with the decreased integrin beta(3) expression. Replenishing these ligands to the starved SMMC-7721 stable transfectants effectively restored the proapoptotic function of integrin beta(3).
conclusionsDown-regulation of integrin beta(3) and its ligands in liver is related to the aggressive growth of HCC. Thus, reconstitution of integrin beta(3) in HCC may be a potential therapeutic approach to inhibit aggressive growth of liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.